Sign in
BBIO Stock Price, Chart, Stats & News
BridgeBio Pharma, Inc.
Save
12.98B
Market cap
–
Current P/E
–
Forward P/E
BBIO chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 94.37% |
Operating margin | -113.35% |
Pretax margin | -146.39% |
Net margin | -145.26% |
Effective tax rate | -0.08% |
ROA | -77.92% |
ROE | 39.18% |
D/E | -1.31x |
Interest coverage ratio | -5.50x |
BBIO valuation
P/E | – |
P/S | 26.91x |
P/B | -6.62x |
P/CF | -30.83x |
P/FCF | -29.53x |
P/OCF | -30.83x |
PEG | -1.97x |
EV multiple | -18.24x |
About
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM).
Similar securities
Based on sector and market capitalization
Report issue